^
    4d
    AVTA 20-01: Safety and Efficacy of APG-157 in Head and Neck Cancer (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, Aveta Biomics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    4d
    A Randomized Phase II Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, University of Chicago
    New P2 trial
    |
    carboplatin • paclitaxel • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    5d
    DECT-CEco: Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and Oropharynx (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, University Hospital, Strasbourg, France
    New trial
    6d
    NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov)
    P1/2, N=140, Recruiting, Novita Pharmaceuticals, Inc. | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    NP-G2-044
    7d
    Prognostic significance of p16 and immune cell infiltration in recurrent/metastatic head and neck squamous cell carcinoma treated with PD-1 inhibition: a national DAHANCA cohort study. (PubMed, Oral Oncol)
    All patients were PD-L1 positive with histologically confirmed rmHNSCC treated with pembrolizumab or nivolumab monotherapy. This subgroup was characterized by p16+ OPC along with concurrent above median levels of FOXP3 and CD68. PD-L1 alone showed no significant association with outcomes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • STING (stimulator of interferon response cGAMP interactor 1) • CD68 (CD68 Molecule) • FOXP3 (Forkhead Box P3) • CEACAM8 (CEA Cell Adhesion Molecule 8)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab)
    7d
    Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=335, Recruiting, Shandong Cancer Hospital and Institute
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    TheraCIM (nimotuzumab)
    11d
    Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Emory University | Trial completion date: Oct 2025 --> Jul 2026
    Trial completion date
    |
    tolinapant (ASTX660)
    12d
    Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (clinicaltrials.gov)
    P3, N=636, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • cisplatin • ABP 206 (nivolumab biosimilar)
    12d
    Shortened Course Adjuvant Radiotherapy Following TORS (clinicaltrials.gov)
    P2, N=104, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Trial primary completion date: Dec 2025 --> Apr 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date
    12d
    Immature squamous metaplastic epithelium of Weber's glandular duct: a significant origin of HPV-independent oropharyngeal squamous cell carcinoma in the base of the tongue. (PubMed, J Cancer Res Clin Oncol)
    Weber's glandular ducts are an important origin of HPV-independent OPSCC. The first animal model replicating this process offers an essential platform for studying HPV-independent OPSCC.
    Journal
    |
    TP63 (Tumor protein 63)
    13d
    First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients (clinicaltrials.gov)
    P2, N=32, Recruiting, Wake Forest University Health Sciences | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel
    14d
    Neo-Margin: De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=356, Not yet recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P3 trial
    |
    Erbitux (cetuximab) • cisplatin